BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics

Louise Hamilton, Nick Barkham, Ashok Bhalla, Robin Brittain, Debbie Cook, Gareth Jones, Kirsten Mackay, David Marshall, Helena Marzo-Ortega, Daniel Murphy, Claire Riddell, Raj Sengupta, Stefan Siebert, Liz Van Rossen, Karl Gaffney, BSR and BHPR Standards, Guidelines and Audit Working Group

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Axial SpA (axSpA) is a chronic inflammatory condition predominantly involving the spine and sacroiliac joints (SIJ), with or without extra-spinal manifestations including peripheral arthritis, enthesitis, iritis, psoriasis and IBD. Individuals with axSpA experience significant pain, stiffness and lack of function that translates into important health care costs and increased mortality.

AxSpA can be classified into two subgroups: radiographic axSpA, commonly referred to as AS, and non-radiographic axSpA (nr-axSpA). The primary difference between these two subgroups is the presence or absence of defined structural changes in the SIJ as detected on plain radiography. Although patients with nr-axSpA do not fulfil the modified New York criteria for AS [1], their burden of disease is similar [2] and they may derive as much benefit from treatment as patients with established AS.

NICE has accredited the process used by the BSR to produce its treatment of axial spondyloarthritis with biologics guidance. Accreditation is valid for 5 years from 10 June 2013. More information on accreditation can be viewed at www.nice.org.uk/accreditation. For full details on our accreditation visit: www.nice.org.uk/accreditation.

This revision of the 2005 BSR guidelines [3] provides evidence-based guidance for UK clinicians prescribing biologic drugs for adult patients across the spectrum of axSpA. This includes the criteria for starting treatment, the choice of drug and assessing response to treatment. Peripheral spondyloarthritis and juvenile SpA are outside the scope of these guidelines, and readers are referred to the BSR 2012 guidelines for the management of PsA [4].
Original languageEnglish
Pages (from-to)313-316
Number of pages4
JournalRheumatology
Volume56
Issue number2
Early online date24 Aug 2016
DOIs
Publication statusPublished - 1 Feb 2017

Fingerprint

Accreditation
Ankylosing Spondylitis
Biological Products
Guidelines
Sacroiliac Joint
Iritis
Therapeutics
Drug Prescriptions
Psoriasis
Radiography
Health Care Costs
Arthritis
Spine
Pain
Mortality
Pharmaceutical Preparations

Keywords

  • ankylosing spondylitis
  • axial spondyloarthritis
  • anti-TNF
  • biologic
  • guideline
  • treatment

Cite this

Hamilton, L., Barkham, N., Bhalla, A., Brittain, R., Cook, D., Jones, G., ... BSR and BHPR Standards, Guidelines and Audit Working Group (2017). BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics. Rheumatology, 56(2), 313-316. https://doi.org/10.1093/rheumatology/kew223

BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics. / Hamilton, Louise; Barkham, Nick; Bhalla, Ashok; Brittain, Robin; Cook, Debbie; Jones, Gareth; Mackay, Kirsten; Marshall, David; Marzo-Ortega, Helena; Murphy, Daniel; Riddell, Claire; Sengupta, Raj; Siebert, Stefan; Van Rossen, Liz; Gaffney, Karl; BSR and BHPR Standards, Guidelines and Audit Working Group.

In: Rheumatology, Vol. 56, No. 2, 01.02.2017, p. 313-316.

Research output: Contribution to journalArticle

Hamilton, L, Barkham, N, Bhalla, A, Brittain, R, Cook, D, Jones, G, Mackay, K, Marshall, D, Marzo-Ortega, H, Murphy, D, Riddell, C, Sengupta, R, Siebert, S, Van Rossen, L, Gaffney, K & BSR and BHPR Standards, Guidelines and Audit Working Group 2017, 'BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics', Rheumatology, vol. 56, no. 2, pp. 313-316. https://doi.org/10.1093/rheumatology/kew223
Hamilton, Louise ; Barkham, Nick ; Bhalla, Ashok ; Brittain, Robin ; Cook, Debbie ; Jones, Gareth ; Mackay, Kirsten ; Marshall, David ; Marzo-Ortega, Helena ; Murphy, Daniel ; Riddell, Claire ; Sengupta, Raj ; Siebert, Stefan ; Van Rossen, Liz ; Gaffney, Karl ; BSR and BHPR Standards, Guidelines and Audit Working Group. / BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics. In: Rheumatology. 2017 ; Vol. 56, No. 2. pp. 313-316.
@article{265eb8926ead467198d0e61b880aace1,
title = "BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics",
abstract = "Axial SpA (axSpA) is a chronic inflammatory condition predominantly involving the spine and sacroiliac joints (SIJ), with or without extra-spinal manifestations including peripheral arthritis, enthesitis, iritis, psoriasis and IBD. Individuals with axSpA experience significant pain, stiffness and lack of function that translates into important health care costs and increased mortality.AxSpA can be classified into two subgroups: radiographic axSpA, commonly referred to as AS, and non-radiographic axSpA (nr-axSpA). The primary difference between these two subgroups is the presence or absence of defined structural changes in the SIJ as detected on plain radiography. Although patients with nr-axSpA do not fulfil the modified New York criteria for AS [1], their burden of disease is similar [2] and they may derive as much benefit from treatment as patients with established AS.NICE has accredited the process used by the BSR to produce its treatment of axial spondyloarthritis with biologics guidance. Accreditation is valid for 5 years from 10 June 2013. More information on accreditation can be viewed at www.nice.org.uk/accreditation. For full details on our accreditation visit: www.nice.org.uk/accreditation.This revision of the 2005 BSR guidelines [3] provides evidence-based guidance for UK clinicians prescribing biologic drugs for adult patients across the spectrum of axSpA. This includes the criteria for starting treatment, the choice of drug and assessing response to treatment. Peripheral spondyloarthritis and juvenile SpA are outside the scope of these guidelines, and readers are referred to the BSR 2012 guidelines for the management of PsA [4].",
keywords = "ankylosing spondylitis, axial spondyloarthritis, anti-TNF, biologic, guideline, treatment",
author = "Louise Hamilton and Nick Barkham and Ashok Bhalla and Robin Brittain and Debbie Cook and Gareth Jones and Kirsten Mackay and David Marshall and Helena Marzo-Ortega and Daniel Murphy and Claire Riddell and Raj Sengupta and Stefan Siebert and {Van Rossen}, Liz and Karl Gaffney and {BSR and BHPR Standards, Guidelines and Audit Working Group}",
year = "2017",
month = "2",
day = "1",
doi = "10.1093/rheumatology/kew223",
language = "English",
volume = "56",
pages = "313--316",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "OXFORD UNIV PRESS INC",
number = "2",

}

TY - JOUR

T1 - BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics

AU - Hamilton, Louise

AU - Barkham, Nick

AU - Bhalla, Ashok

AU - Brittain, Robin

AU - Cook, Debbie

AU - Jones, Gareth

AU - Mackay, Kirsten

AU - Marshall, David

AU - Marzo-Ortega, Helena

AU - Murphy, Daniel

AU - Riddell, Claire

AU - Sengupta, Raj

AU - Siebert, Stefan

AU - Van Rossen, Liz

AU - Gaffney, Karl

AU - BSR and BHPR Standards, Guidelines and Audit Working Group

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Axial SpA (axSpA) is a chronic inflammatory condition predominantly involving the spine and sacroiliac joints (SIJ), with or without extra-spinal manifestations including peripheral arthritis, enthesitis, iritis, psoriasis and IBD. Individuals with axSpA experience significant pain, stiffness and lack of function that translates into important health care costs and increased mortality.AxSpA can be classified into two subgroups: radiographic axSpA, commonly referred to as AS, and non-radiographic axSpA (nr-axSpA). The primary difference between these two subgroups is the presence or absence of defined structural changes in the SIJ as detected on plain radiography. Although patients with nr-axSpA do not fulfil the modified New York criteria for AS [1], their burden of disease is similar [2] and they may derive as much benefit from treatment as patients with established AS.NICE has accredited the process used by the BSR to produce its treatment of axial spondyloarthritis with biologics guidance. Accreditation is valid for 5 years from 10 June 2013. More information on accreditation can be viewed at www.nice.org.uk/accreditation. For full details on our accreditation visit: www.nice.org.uk/accreditation.This revision of the 2005 BSR guidelines [3] provides evidence-based guidance for UK clinicians prescribing biologic drugs for adult patients across the spectrum of axSpA. This includes the criteria for starting treatment, the choice of drug and assessing response to treatment. Peripheral spondyloarthritis and juvenile SpA are outside the scope of these guidelines, and readers are referred to the BSR 2012 guidelines for the management of PsA [4].

AB - Axial SpA (axSpA) is a chronic inflammatory condition predominantly involving the spine and sacroiliac joints (SIJ), with or without extra-spinal manifestations including peripheral arthritis, enthesitis, iritis, psoriasis and IBD. Individuals with axSpA experience significant pain, stiffness and lack of function that translates into important health care costs and increased mortality.AxSpA can be classified into two subgroups: radiographic axSpA, commonly referred to as AS, and non-radiographic axSpA (nr-axSpA). The primary difference between these two subgroups is the presence or absence of defined structural changes in the SIJ as detected on plain radiography. Although patients with nr-axSpA do not fulfil the modified New York criteria for AS [1], their burden of disease is similar [2] and they may derive as much benefit from treatment as patients with established AS.NICE has accredited the process used by the BSR to produce its treatment of axial spondyloarthritis with biologics guidance. Accreditation is valid for 5 years from 10 June 2013. More information on accreditation can be viewed at www.nice.org.uk/accreditation. For full details on our accreditation visit: www.nice.org.uk/accreditation.This revision of the 2005 BSR guidelines [3] provides evidence-based guidance for UK clinicians prescribing biologic drugs for adult patients across the spectrum of axSpA. This includes the criteria for starting treatment, the choice of drug and assessing response to treatment. Peripheral spondyloarthritis and juvenile SpA are outside the scope of these guidelines, and readers are referred to the BSR 2012 guidelines for the management of PsA [4].

KW - ankylosing spondylitis

KW - axial spondyloarthritis

KW - anti-TNF

KW - biologic

KW - guideline

KW - treatment

U2 - 10.1093/rheumatology/kew223

DO - 10.1093/rheumatology/kew223

M3 - Article

C2 - 27558584

VL - 56

SP - 313

EP - 316

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 2

ER -